Swiss pharmaceutical company Santhera Pharmaceuticals (SIX:SANN) announced on Tuesday the signing of an exclusive agreement with Ireland-based pharmaceutical distribution company Uniphar to manage the distribution of AGAMREE (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

Santhera expects sales to begin on a named patient basis in Q1 2026, with broader commercial sales anticipated in late 2026 following market authorisation and pricing agreement. Santhera will receive a percentage of net sales as payment, consistent with the company's previous distribution agreements. According to the company, this agreement will help ensure that patients across these countries have timely access to this innovative therapy.

Dario Eklund, Santhera CEO, said: "We are excited to partner with Uniphar for the distribution of AGAMREE in GCC (Gulf Cooperation Council) countries. Uniphar's strong regional presence, combined with its proven expertise in early and expanded access programmes, will help address the significant unmet need for boys and men living with DMD in these countries."

Santhera's global rollout of AGAMREE already includes multiple regions across North America, Europe and Asia.